Advertising
Showing 1 to 15 of 40 entries
HOLD

This company is a good one, but sunglasses are a discretionary item. Now is not the time to initiate a position – if you own it, hold.

biotechnology / pharmaceutical
DON'T BUY

This company makes eyewear and owns Lenscrafters. He is not a big fan of a company that owns both lens manufacturing and eyewear as they are viewed as competitors by other eyewear manufacturers.

biotechnology / pharmaceutical
COMMENT

Has merged with Essilor (EI-FP), and is just waiting for EU approval. If interested in Luxottica, you should think of Essilor instead. This merger will give you a gargantuan conglomerate that will dominate pricing. Essilor is not just eyeglasses, 2/3 of Chinese are myopic and in need of reading glasses. With the aging population there is still good opportunity in Essilor moving forward. Dividend growth has been roughly 15% a year, double what the growth rate is on average.

biotechnology / pharmaceutical
COMMENT

Merging with Essilor (EI-FP), the leading lens producer, and a lot of people view this as very positive, but isn’t sure he feels the same. Luxottica is the parent of LensCrafters, and he wonders why they would do business with their competitor. Prefers Hoya Corp (7741-JP).

biotechnology / pharmaceutical
DON'T BUY

He prefers another in the vision space. He likes the vision space, though. There is aging going on in the world. The use of computer screens has lead to more needs for vision correction.

biotechnology / pharmaceutical
COMMENT

He is positive on this name because of the moats, the amount of capital you would have to create, to take the company on. They’ve been hurt because they’ve had a big expansion on their PE multiple up to 30X, and has come back down again because it is not growing as fast as the analysts want them to. They have very little competition and they are in e-commerce.

biotechnology / pharmaceutical
COMMENT

Had no idea how dominant their position was, not just in retail eyewear in terms of exclusive retail rights for a lot of brands, but also owning the optical retail locations as well. This is as close to a monopoly as you can be. A phenomenal business and the returns are great. When you have businesses that have to make transitions from the individual to a corporation, you can run into a lot of problems. Great business, but when the management team changed he stopped following it.

biotechnology / pharmaceutical
TOP PICK

We know this through the 6500 retail stores including Sunglass Hut and LensCrafters. They also have the brand names of Ray-Ban and others. Also, they are the exclusive licensed supplier and distributor of Google Glass, and have just signed a deal with Intel to do work on smart glasses with Oakley. Underneath all of that there is a demographic wave of us getting older and needing glasses. A beautiful name and low volatility. Dividend yield of 1.2%.

biotechnology / pharmaceutical
BUY
Domiciled in Italy. Facilitating company. Higher end sunglasses. Margin might be difficult to create. 75% of revenue from US. He would add it for new clients.
biotechnology / pharmaceutical
BUY
Integrated eyeglass company. Manufacture for a whole host of brands, some of which they wholly own. They also retail. Well-run company. Gets far more of its revenue from the US than it does from Europe. Should be able to grow its earnings at high single-digit/low double-digit for many years to come.
biotechnology / pharmaceutical
TOP PICK
Sunglasses. Italian domiciled company and get about 25% of revenues from European operations and the rest from outside of Europe. Have done fairly well through recessionary times. If spending gets back up to luxury levels, they should do even better.
biotechnology / pharmaceutical
COMMENT
Dominate eyeglasses/sunglasses sector. Their competition is very fragmented globally. Growth in China and other emerging markets is going to grow over time. Just moved into South America. Stock is a little rich right now.
biotechnology / pharmaceutical
COMMENT
People still need glasses, usually every 2 years. Sales were down and margins have declined. Suspended the dividend because they want to pay down some debt from their Oakley acquisition. Oakley is going great guns, as is the lower end of their business. As the economy turns around, they will start to improve.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Dec 6/07. Down 42%.) Designer glasses. Discretionary consumer products will have a negative impact during recessions. Still likes. Would buy more if it got cheaper. 3.5% yield. Getting into China in a big way.
biotechnology / pharmaceutical
BUY
Chance to dollar cost average. Will expand retail stores in China (up to 1000 stores) in next 3 years. Still growing 15-20% range despite economy slowing down.
biotechnology / pharmaceutical
Showing 1 to 15 of 40 entries

Luxottica(LUXTY-5) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Luxottica is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Luxottica(LUXTY-5) Frequently Asked Questions

What is Luxottica stock symbol?

Luxottica is a OTC stock, trading under the symbol LUXTY-5 on the (). It is usually referred to as or LUXTY-5

Is Luxottica a buy or a sell?

In the last year, there was no coverage of Luxottica published on Stockchase.

Is Luxottica a good investment or a top pick?

Luxottica was recommended as a Top Pick by on . Read the latest stock experts ratings for Luxottica.

Why is Luxottica stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Luxottica worth watching?

In the last year, there was no coverage of Luxottica published on Stockchase.

What is Luxottica stock price?

On , Luxottica (LUXTY-5) stock closed at a price of $.